John Butler, Akebia CEO
Akebia's anemia drug flunked Covid study — but count the bruised biotech 'extremely encouraged'
For as long as it’s existed — since 2007 and counting — Akebia has always billed itself as a kidney disease specialist. But as it grapples with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
